Cure­Vac grabs a $29.5M round to fu­el its mR­NA de­vel­op­ment ef­forts

Cure­Vac, the Ger­man mR­NA biotech, has added a cou­ple of new in­vestors to the mix who are chip­ping $29.5 mil­lion in­to the op­er­a­tion as it nears a crit­i­cal junc­ture on the R&D side of the busi­ness.

The Tübin­gen-based biotech, which has been pri­mar­i­ly backed by Ger­man bil­lion­aire Di­et­mar Hopp along with ad­di­tion­al fund­ing from Bill Gates’ foun­da­tion, says that Baden- Würt­tem­ber­gis­che Ver­sorgungsanstalt für Ärzte, Zah­närzte und Tierärzte (via the LBBW As­set Man­age­ment In­vest­ment­ge­sellschaft mbH, Stuttgart) and Lan­deskred­it­bank Baden-Würt­tem­berg added the funds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER